idh
No description yet: the sentence for this tag has not been written. 4 records carry it: 2 people, 2 biomarkers.
By kind
4 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Eytan M. Stein Chief, Leukemia Service, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led the enasidenib and revumenib trials that brought IDH2 and menin inhibitors to acute leukaemia. | Acute myeloid leukaemia, Acute lymphoblastic leukaemia | none | aml, menin, early-phase | ||
IDH1 R132 mutation IDH1, IDH2 IDH1 R132 mutations turn a metabolic enzyme into a producer of the oncometabolite 2-HG. They define lower-grade gliomas and occur in acute myeloid leukaemia and bile duct cancer, each with an approved IDH1 inhibitor. | Acute myeloid leukaemia, IDH1- and IDH2-mutated acute myeloid leukaemia, Biliary tract cancer | none | biomarker | ||
IDH2 mutation (R140 and R172) IDH1, IDH2 IDH2 mutations at codons 140 and 172 do the same job as IDH1 R132, producing 2-HG. Enasidenib is approved for relapsed AML with them, and vorasidenib for grade 2 gliomas with either IDH gene mutated. | Acute myeloid leukaemia, IDH1- and IDH2-mutated acute myeloid leukaemia, Astrocytoma, IDH-mutant | none | biomarker | ||
Ingo K. Mellinghoff Chair, Department of Neurology, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led INDIGO, the trial that made vorasidenib the first targeted therapy for low-grade IDH-mutant glioma. | Glioma & glioblastoma | none | glioma, targeted-therapy |